Zosano Pharma Corp  

(Public, NASDAQ:ZSAN)   Watch this stock  
Find more results for zosano
-0.017 (-3.29%)
Jan 18 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.46 - 0.52
52 week 0.46 - 3.54
Open 0.51
Vol / Avg. 735,479.00/636,154.00
Mkt cap 19.28M
P/E     -
Div/yield     -
EPS -1.18
Shares 39.46M
Beta     -
Inst. own 35%
Feb 27, 2018
Q4 2017 Zosano Pharma Corp Earnings Release (Estimated) Add to calendar
Nov 9, 2017
Q3 2017 Zosano Pharma Corp Earnings Call
Nov 9, 2017
Q3 2017 Zosano Pharma Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -104.35% -90.07%
Return on average equity -174.52% -192.55%
Employees 39 -
CDP Score - -


34790 Ardentech Ct
FREMONT, CA 94555-3657
United States - Map
+1-510-7451200 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability. The Company's short-wear-time transdermal patch consists of an array of titanium microneedles that is coated with its formulation of an approved drug and attached to an adhesive patch. When the patch is applied with its hand-held applicator, the microneedles painlessly penetrate the skin, resulting in rapid dissolution and absorption of the drug coating through the capillary bed. Its product candidates include ZP-Triptan, ZP-Glucagon and ZP-PTH. ZP-PTH is a formulation of teriparatide, a synthetic form of parathyroid hormone. ZP-Glucagon is a formulation of glucagon.

Officers and directors

John P. Walker Chairman of the Board, President, Chief Executive Officer
Age: 68
Bio & Compensation  - Reuters
Georgia L. Erbez Interim Chief Financial Officer, Chief Business Officer
Age: 49
Bio & Compensation  - Reuters
Eric Scharin Vice President - Technical Operations
Bio & Compensation  - Reuters
Thorsten von Stein M.D. Ph.D. Chief Medical Officer
Bio & Compensation  - Reuters
Joseph P. Hagan Director
Age: 48
Bio & Compensation  - Reuters
Kenneth R. Greathouse Independent Director
Bio & Compensation  - Reuters
Troy E. Wilson Ph.D. J.D. Independent Director
Age: 48
Bio & Compensation  - Reuters
Kleanthis G. Xanthopoulos Ph.D. Independent Director
Age: 57
Bio & Compensation  - Reuters